
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Sharps Technology Inc (STSS)


- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)

(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: STSS (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $22
1 Year Target Price $22
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.46% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() | ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 134.60M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 1 | Beta 2.16 | 52 Weeks Range 3.36 - 1248.27 | Updated Date 10/17/2025 |
52 Weeks Range 3.36 - 1248.27 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1196.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1349.84% |
Management Effectiveness
Return on Assets (TTM) -50.38% | Return on Equity (TTM) -6.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 182455305 | Price to Sales(TTM) 604.34 |
Enterprise Value 182455305 | Price to Sales(TTM) 604.34 | ||
Enterprise Value to Revenue 819.21 | Enterprise Value to EBITDA -2.19 | Shares Outstanding 26600848 | Shares Floating 1021853 |
Shares Outstanding 26600848 | Shares Floating 1021853 | ||
Percent Insiders 0.13 | Percent Institutions 0.07 |
Upturn AI SWOT
Sharps Technology Inc

Company Overview
History and Background
Sharps Technology Inc. focuses on the design, development, and manufacturing of safety syringe products. It aims to reduce needlestick injuries and prevent cross-contamination in healthcare settings. The company has been involved in the development of various safety-engineered medical devices.
Core Business Areas
- Safety Syringes: Design, manufacturing, and sale of ultra-low waste space safety syringes. These syringes are designed to minimize medication waste and reduce the risk of needlestick injuries and cross-contamination. Target market are clinicians and drug manufacturers for prefilled syringes and vaccine delivery.
Leadership and Structure
Details on the specific leadership team and organizational structure require deeper research using public filings and company website. The company is headed by Robert Hayes (CEO) and there is also Sanjay Nayar (CFO).
Top Products and Market Share
Key Offerings
- Ultra-Low Waste Space Safety Syringes: These syringes are designed to minimize medication waste. Competitors include Becton Dickinson (BDX) and Smiths Medical. Specific market share data is difficult to determine without proprietary information but Sharps Tech is trying to disrupt this market.
Market Dynamics
Industry Overview
The medical device industry is driven by technological advancements, regulatory requirements, and the increasing need for safer and more efficient healthcare solutions. The safety syringe market is growing due to concerns about needlestick injuries and the spread of infectious diseases.
Positioning
Sharps Technology Inc. is positioned as an innovator in the safety syringe market, focusing on reducing medication waste and improving safety for healthcare workers. Its competitive advantage lies in its patented ultra-low waste space design.
Total Addressable Market (TAM)
The global prefilled syringes market is estimated to be in the billions of dollars. Sharps Tech is positioned to capture a portion of this TAM with its specialized safety syringes.
Upturn SWOT Analysis
Strengths
- Patented ultra-low waste space design
- Focus on safety and reducing needlestick injuries
- Potential for partnerships with pharmaceutical companies
- Manufacturing scalability in Buffalo, NY
Weaknesses
- Limited brand recognition compared to established players
- Potential dependence on key partnerships
- Financial performance and capital structure require significant growth
- Limited product portfolio.
Opportunities
- Growing demand for safety syringes
- Expanding into new markets and applications (e.g., veterinary medicine)
- Partnerships with pharmaceutical companies for prefilled syringes
- Acquisition by a large player
Threats
- Competition from established medical device companies (BDX)
- Regulatory changes and compliance requirements
- Economic downturn affecting healthcare spending
- Patent litigation or challenges to intellectual property
Competitors and Market Share
Key Competitors
- Becton Dickinson (BDX)
- Gerresheimer AG (GRRMF)
- Smiths Medical (Part of ICU Medical (ICUI))
Competitive Landscape
Sharps Technology Inc. is a smaller player in the market compared to established giants like Becton Dickinson. It focuses on specific niche with patented design, competing on innovation and safety features, but faces challenges in scaling production and gaining market share against larger, more established competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require financial data over several years. Unable to provide without current financial statements.
Future Projections: Future growth projections are dependent on partnerships, market adoption, and manufacturing scalability. Analyst estimates are currently difficult to determine for this company.
Recent Initiatives: Recent strategic initiatives are centered around scaling manufacturing capacity and securing partnerships with pharmaceutical companies.
Summary
Sharps Technology Inc. is a small, innovative company focused on safety syringe technology. Its patented design and focus on reducing medication waste provide a competitive advantage. However, it faces significant challenges from larger, established players and needs to demonstrate its ability to scale production and secure key partnerships to achieve sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is based on publicly available data and analyst estimates, and should not be considered as financial advice. Market conditions and company performance are subject to change. This analysis is for informational purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sharps Technology Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2022-04-14 | CEO - | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 55 | Website https://sharpstechnology.com |
Full time employees 55 | Website https://sharpstechnology.com |
Sharps Technology, Inc., a medical device and pharmaceutical packaging company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems. The company was incorporated in 2017 and is based in Melville, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.